Colorectal Cancer Metastatic
Conditions
Keywords
Thermoablation
Brief summary
Hepatic metastases of colorectal cancer (CRC) are partially necrotic tumors mainly vascularized by the hepatic artery. When resectable, these metastases must be removed with a safety margin of 1 mm. Resection margins greater than 1 cm are associated with better disease-free survival and no local recurrence. Thermoablation systems allow for ablation zones of approximately 4.5-5 cm in diameter. For tumors \<3 cm, subject to perfect targeting, it is possible to obtain ablation margins of 1 cm, which would greatly reduce the local recurrence rate. Accurate assessment of these tumor boundaries and characterization of these margins are paramount to ensure complete ablation. Thermoablation for these small liver metastases (\<3cm) has shown equivalent efficacy to surgery in terms of recurrence and survival with fewer complications. Thermoablation treatment is indicated for patients with stable disease undergoing chemotherapy. This leads to liver remodeling and metastases become difficult to see on ultrasound and CT scans. The study authors hypothesize that the porto-scanner guidance technique with Angio-CT for thermoablation treatment of CRC liver metastases will allow a better exploration of these metastases by allowing a better identification of the margins and thus ensure a more accurate and complete treatment for patients.
Interventions
PROCEDUREThermoablation with standard CT guidance
Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
PROCEDUREThermoablation with porto-scanner guidance with Angio-CT
Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * Patients with CRC liver metastases (\< 3 lesions, \< 3 cm in diameter), proven on MRI and/or Positron Emission Tomography scan. * Patient eligible for thermoablation requiring CT guidance (at least one metastasis not visible on ultrasound). * Treatment by thermoablation validated in multidisciplinary meeting. * Eastern Cooperative Oncology Group performance score 0-2. * ASA score 1-3. * Life expectancy of more than 3 months. * Renal function allowing iodinated contrast injection (clearance \> 30 mL/min), normal liver function (bilirubin \< 35 µmol/L) and hemostasis assessment allowing percutaneous procedure (PT \> 50%, platelets \> 50 G/L, anticoagulant treatment to be stopped). * Postmenopausal patient or patient with effective contraception (hormonal or mechanical) * Pregnancy test (bHCG blood) negative in the month prior to inclusion for patients of childbearing age * Patients with a history of radical treatment (surgery, radiofrequency or stereotactic radiotherapy) for liver metastases more than 6 months old. * Patient presenting a recurrence at a distance from the treated lesion (more than 1 cm from the scar).
Exclusion criteria
* The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Lesion not eligible for thermoablation (proximity of the liver hilum and the main bile duct). * Uncorrectable abnormalities of liver or blood functions (coagulation). * Severe allergy to contrast media. * Contraindication to MRI (pacemaker, neuro-stimulator, cochlear implant, metallic heart valve, claustrophobia). * Uncontrolled infection. * Any physical, physiological or psychological condition incompatible with study participation or patient compliance. * Pregnant, parturient or nursing patient. * Contraindications mentioned in the Product Monographs of the following drugs: * FLUCIS: Hypersensitivity to the active substance (fludeoxyglucose (18F)) or to one of the excipients. * VISIPAQUE 320 * Hypersensitivity to the active substance or to any of the excipients mentioned in section 6.1. * History of immediate major or delayed cutaneous reaction (see section 4.8) to the injection of iodinated contrast material (Visipaque), * Decompensated cardiac insufficiency with systemic injection (only concerns high osmolarity ionic products), * Overt thyreotoxicosis, * Hysterosalpingography in pregnancy * patient with a history of radical treatment for liver metastases (surgery, thermoablation, stereotactic radiotherapy) less than 6 months old. * patient with recurrence within 1 cm of the scar.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups | 3 months | Percentage, where complete response is defined as complete ablation of the treated lesions (complete disappearance of enhancement and hypermetabolism) with no new lesions appearing, determined on imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in response rate per lesion between the groups | 3 months | Percentage |
| Difference in distant recurrences between the groups | 12 Months | — |
| Difference in local recurrences between the groups | 12 Months | Yes/no presence of recurrence |
| Recurrence free survival between the groups | 12 months | Days |
| Local recurrence-free survival between the groups | 12 months | Days |
| Distant recurrence-free survival between the groups | 12 months | Days |
| Difference in time until recurrence between the groups | 12 months | Days |
| Size of the lesions | 3 months | mm |
| Diameter of the tumor in axial | 3 months | mm |
| Location of the lesions | 3 months | Dome/left liver/sub capsular/contact with a large vessel (\> 5mm) |
| Size of the ablation area | 3 months | mm |
| Feasibility of porto-scanner | End of procedure (Day 0) | Presence of metastatic lesions by scanner yes/no |
| Complications arising during intervention | End of procedure (Day 0) until 3 months | Complications related to the approach (vascular complications), related to the percutaneous procedure (hematoma, active bleeding) or related to the treatment; Clavien-Dindo classification |
| Reason for for failure of technique requiring switch to different guidance technique | End of procedure (Day 0) | Vascular problem (failure of catheterization) or problem of elevation (no optimal elevation of the liver allowing guidance) |
| Cost estimates for both guidance techniques during intervention | End of procedure (Day 0) | Cost differential of the two guidance techniques for thermoablation of colorectal cancer liver metastases from the point of view of the healthcare facility |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORJulien Frandon
CHU de Nimes
Outcome results
None listed